Clinical trials: Moderate COVID-19-infection
Covid19
Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19
This single-center, open-label, 2 arm parallel-group, randomized, interventional prospective exploratory study in 20 subjects aimed to evaluate safety and explore putative clinical benefits of Silmitasertib 1000 mg BID dose in…
- Trial name
- NCT04663737
- Testing
- Silmitasertib, SOC
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Senhwa Biosciences, Inc.
Coronavirus Infection
COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19
The most prevalent complication of COVID-19 infection is respiratory failure from severe acute respiratory syndrome (SARS), the leading cause of mortality.
- Trial name
- COMBATCOVID19 (NCT04363437)
- Testing
- Colchicine, Usual Care
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Maimonides Medical Center
COVID-19
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment
The primary objective of this study was to evaluate the efficacy of 2 remdesivir (RDV) regimens compared to standard of care (SOC), with respect to clinical status assessed by a 7-point ordinal scale on Day 11.
- Trial name
- NCT04292730
- Testing
- Remdesivir, Standard of Care
- Where
- 184 sites in United States, China and 13 more
- Volunteers
- 1,113 people
- Sponsor
- Gilead Sciences
COVID-19
Safety, Tolerability, and Treatment Effect of Belnacasan in Patients With COVID-19
The purpose of this trial is to assess the safety, tolerability and treatment effect of the orally administered Caspase-1 inhibitor, belnacasan, for the treatment of patients with mild to moderate COVID-19 and to generate proof…
- Trial name
- NCT05164120
- Testing
- Belnacasan
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- MedStar Health